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Clinically relevant cancers must establish effi-
cient mechanisms of escaping destruction by 
the immune system. One of the most successful 
strategies of tumor-induced immune evasion   
is the recruitment, expansion, and activation of 
CD4+ Foxp3+ T reg cells (1, 2). T reg cells can 
potently inhibit immune responses and consti-
tute a major barrier for eliciting effective anti-
tumor immunity (3). Cancer patients suffering 
from a variety of malignancies have elevated 
numbers of tumor-associated T reg cells, and 
increased T reg cell levels correlate with poor 
prognosis (4–10).
Not surprisingly, the inactivation or depletion 
of T reg cells has been actively pursued as means 
to develop more potent immune therapies.   
Depletion of T reg cells has been accomplished 
with alkylating agents such as cyclophosphamide 
(CTX) (11–17). As a chemotherapeutic drug, 
CTX is administered clinically at doses that di-
rectly kill tumor cells. However, immunologists 
have known for decades that CTX has significant 
effects on the immune system that can promote a 
favorable antitumor immune response (14, 18).
In addition to specific effects of CTX on   
T reg cells, lymphocytes recovering from CTX-
induced lymphopenia undergo homeostatic 
proliferation that can activate tumor-specific T 
cells (19). Reconstitution from CTX-induced 
lymphopenia is associated with elevated levels   
of numerous proinflammatory cytokines, which 
favors an antitumor immune response (20, 21). 
Moreover, direct tumor cell death can be as-
sociated with tissue necrosis and the release of 
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Expansion and recruitment of CD4+ Foxp3+ regulatory T (T reg) cells are mechanisms used 
by growing tumors to evade immune elimination. In addition to expansion of effector  
T cells, successful therapeutic interventions may require reduction of T reg cells within the 
tumor microenvironment. We report that the combined use of the alkylating agent cyclo-
phosphamide (CTX) and an agonist antibody targeting the co-stimulatory receptor OX40 
(OX86) provides potent antitumor immunity capable of regressing established, poorly 
immunogenic B16 melanoma tumors. CTX administration resulted in tumor antigen release, 
which after OX86 treatment significantly enhanced the antitumor T cell response. We 
demonstrated that T reg cells are an important cellular target of the combination therapy. 
Paradoxically, the combination therapy led to an expansion of T reg cells in the periphery. 
In the tumor, however, the combination therapy induced a profound T reg cell depletion 
that was accompanied by an influx of effector CD8+ T cells leading to a favorable T effector/
T reg cell ratio. Closer examination revealed that diminished intratumoral T reg cell levels 
resulted from hyperactivation and T reg cell–specific apoptosis. Thus, we propose that CTX 
and OX40 engagement represents a novel and rational chemoimmunotherapy.
© 2009 Hirschhorn-Cymerman et al.  This article is distributed under the terms 
of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the 
first six months after the publication date (see http://www.jem.org/misc/terms 
.shtml). After six months it is available under a Creative Commons License (Attribu-
tion–Noncommercial–Share Alike 3.0 Unported license, as described at http://cre-
ativecommons.org/licenses/by-nc-sa/3.0/).
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and  provide  insight  into  a  novel  mechanism  that  involves 
elimination of T reg cells in the tumor microenvironment.
RESULTS
CTX synergizes with OX40 engagement to promote potent 
antitumor immunity
Administration of OX86 yields weak, ineffective responses to 
poorly immunogenic tumors (43, 44). We sought to increase 
the potency of OX86 treatment by combining it with CTX, 
a drug with both immune-enhancing properties and direct 
antitumor  effects.  Mice  with  6-d  established  B16  tumors 
were treated with a single 250 mg/kg dose of CTX followed 
by 0.5 mg OX86 the next day. Treatment resulted in the 
survival of 75% of animals at day 50 (Fig. 1 A) and regressed 
established tumors (Fig. 1 B). Neither therapy alone provided 
significant tumor protection.
To evaluate the clinical potential of OX86 and CTX 
therapy, we compared it with the combination of CTX and 
monoclonal  antibodies  with  proven  efficacy  in  preclinical 
models, such as anti-CTLA4 (9D9) or anti-CD40 (FGK45) 
(46, 47). We found that OX86 in combination with CTX 
danger signals that enhance tumor antigen cross-presentation 
and cross-priming (22, 23). To increase antitumor immune re-
sponses, CTX has been successfully combined with vaccination 
and adoptive immunotherapy strategies (chemoimmunotherapy) 
in multiple modalities and tumor models (24, 25).
OX40 is a co-stimulatory molecule and member of the 
TNFR family constitutively expressed on T reg cells and in-
ducibly expressed by effector CD4+ T cells upon activation (26). 
Signaling through OX40 up-regulates the expression of anti-
apoptotic Bcl-2 family members, Bcl-2 and Bcl-XL, leading 
to increased clonal expansion and memory responses (17). 
OX40 signaling can also provide co-stimulation to activated 
CD8+ T, NK, and NKT cells (27–30).
Although the function of OX40 has been established for 
effector CD4+ and CD8+ T cells, the biological role that 
OX40 plays on T reg cells is still controversial. Early reports 
have shown that OX40 ligation is crucial for T reg cell ho-
meostasis (31). Young mice deficient in OX40 have reduced 
levels of CD4+ CD25+ T reg cells, and mice overexpressing 
OX40L  possess  elevated  levels  in  the  spleen  and  thymus. 
However, engaging OX40 can abrogate the T reg cell sup-
pressive function and down-regulate Foxp3 expression (31–34). 
Additionally, it has been reported that OX40 ligation pre-
vents the conversion of naive CD4+ T cells into T reg cells 
induced by TGF- and antigen (33, 35).
Given that OX40 engagement can potently stimulate T cells 
and potentially inhibit T reg cells, it has been successfully 
used in the treatment of a variety of transplantable tumors in 
mice (34, 36). Overexpression of OX40L in tumor cell lines 
and dendritic cells induced substantial antitumor immunity 
(37–39). The triggering of OX40 with recombinant soluble 
OX40L or the anti-OX40 agonist monoclonal antibody OX86 
are additional strategies proven to be effective in treating im-
munogenic tumors (40–45). However, targeting OX40 alone 
or in combination with other therapeutic approaches has only 
marginal effects on less immunogenic, more clinically relevant 
mouse tumors.
We hypothesized that OX40 ligation after administration 
of CTX would provide strong antitumor immunity. Indeed, 
we found that OX86 in combination with CTX synergized to 
mediate the regression of established, B16 mouse melanoma 
tumors. We demonstrate that CTX treatment resulted in the 
release of tumor antigens capable of priming effector CD4+ 
and CD8+ T cells, and that OX40 engagement amplified these 
responses. Furthermore, we show that the combination ther-
apy targets T reg cells, inducing previously uncharacterized 
changes in this population. Unexpectedly, OX86 administra-
tion increased the number of T reg cells in the periphery, an 
effect that was exacerbated when OX86 was administered 
with CTX. In contrast, the combination therapy significantly 
reduced the number of T reg cells infiltrating the tumor, with 
a substantial, increased infiltration of effector CD8+ T cells. 
Closer mechanistic examination revealed that the combina-
tion therapy resulted in T reg cell–specific apoptosis, which 
accounted for the reduced intratumoral infiltration. Thus, we 
report a potent, clinically translatable chemoimmunotherapy 
Figure 1.  OX40 engagement synergizes with CTX to provide potent 
antitumor immunity. (A) C57BL/6 mice (n = 15 per group) were injected 
intradermally in the flank with a lethal dose of B16 melanoma. On day 6, 
once tumors were palpable, CTX or PBS was injected. On day 7, mice were 
injected with OX86 or rat IgG. The Kaplan-Meier plot depicts overall survival. 
Similar results were obtained from four independent experiments.  
**, P = 0.0061. (B) C57BL/6 mice (n = 10–15 per group) were treated as in  
A and tumor area was measured periodically. Plots represent the tumor 
diameter of individual mice for each treatment. Similar results were obtained 
from four independent experiments. (C) C57BL/6 mice (n = 10 per group) 
were treated as in A. In some groups, OX86 injection was replaced with 9D9 
(anti-CTLA4) or FGK45 (anti-CD40). Tumor area was measured periodically. 
Results represent mean tumor areas ± SEM for each treatment.JEM VOL. 206, May 11, 2009 
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day with OX86 or IgG, and 5 d later proliferation by CFSE 
dilution was measured in the tumor draining LN (TDLN) or 
at a distant LN (non-DLN) by flow cytometry. In the TDLN, 
pmel-1 cells from the CTX plus OX86–treated group showed 
higher proliferation than any of the therapies alone (Fig. 2 A). 
Although some proliferation was found at the non-DLN in 
both CTX-treated groups (presumably as a result of homeo-
static proliferation caused by CTX administration), a prefer-
ential proliferation was found in mice that received CTX plus 
OX86 compared with animals that received CTX plus IgG. 
Thus, proliferation of tumor-specific T cells was observed pri-
marily in TDLN compared with non-DLN.
To further substantiate our hypothesis, we purified CD8+ 
and CD4+ T cells from spleens of tumor-bearing or naive 
mice subjected to the combination therapy and tested their 
ability to react against B16 and melanoma-specific peptides   
in IFN- ELISPOT assays. Only the CD4+ or CD8+ T cells 
from tumor-bearing mice treated with the combination ther-
apy responded to B16 or APCs pulsed with B16-specific 
peptides (Fig. 2 B). These results strongly suggest that, upon 
CTX administration, antigen is made available for priming by 
drug-induced tumor destruction, and that OX86 aids in the 
expansion of antitumor T cells.
showed a much higher potency than any of the other treat-
ments. Combination therapy with FGK45 had a comparable 
effect to CTX alone, whereas the 9D9 combination provided 
some benefit (Fig. 1 C). Furthermore, the combination ther-
apy promoted the regression of established tumors and/or 
significantly  prolonged  survival  in  other  poorly  immuno-
genic tumor models (4T1 mammary carcinoma, Lewis lung 
carcinoma, and Tramp C2 prostate adenocarcinoma; unpub-
lished data). These experiments demonstrate that administra-
tion of a single dose of CTX synergizes with anti-OX40 
antibody to provide antitumor immunity that can eradicate 
poorly immunogenic tumors.
CTX-induced tumor destruction releases B16 tumor antigen 
that is capable of priming an antitumor immune response  
in the presence of OX86
We  hypothesized  that  partial  destruction  of  the  tumor  by 
CTX releases antigen capable of priming a tumor-specific 
response, and that OX86 enhances the function of tumor-
specific T cells. To test this hypothesis, we transferred CFSE-
labeled TCR transgenic CD8+ T cells specific for the melanoma 
antigen gp100 (pmel-1 cells) (48) into tumor-bearing mice 
pretreated with CTX or PBS. Mice were injected the next 
Figure 2.  Tumor destruction by CTX provides antigen that can prime an antitumor immune response in the presence of OX86. (A) C57BL/6 
Thy1.2 mice (n = 4 per group) were injected with five times the lethal dose of B16 tumor cells in Matrigel. On day 6, groups of mice were treated with CTX 
or PBS. On day 7, all mice received 2 × 106 purified CFSE-labeled CD8+ pmel-1 cells (Thy1.1) and OX86 or rat IgG. On day 13, mice were sacrificed, and a 
single-cell suspension was prepared from inguinal (TDLN) or contralateral cervical LN (non-DLN) and analyzed by flow cytometry. Cells were gated on 
DAPI, CD8+, and Thy1.1+. One representative plot from three independent experiments is shown (percentages are shown). (B) C57BL/6 mice (n = 5 per 
group) were either injected with B16-Matrigel or left as non–tumor-bearing controls. On day 6, mice were injected with CTX, followed by administration 
of OX86 or rat IgG on day 7. 21 d after tumor inoculation, purified CD8+ and CD4+ T cells from pooled spleens were tested by IFN- ELISPOT. Values repre-
sent mean numbers of spots per well ± SEM (n = 3–4 wells). Data shown are representative of four independent experiments.1106 OX40 ENGAGEMENT AND CHEMOTHERAPY SYNERGIZE TO PROVIDE POTENT ANTITUMOR IMMUNITY | Hirschhorn-Cymerman et al.
presence of OX86-biotin in different cell populations. Fig. 4 A 
shows that OX86-biotin was bound preferentially to CD4+ 
T cells. Approximately 50% of CD4+ T cells in the tumor, 
20% in the TDLN, and 30% in the spleen were OX86-
biotin positive, whereas only a small percentage of CD8+ cells 
bound OX86-biotin in the tumor (3%). When we examined 
OX86-biotin binding to different CD4+ subsets, we found that 
OX86 was primarily bound to T reg cells in each of the organs 
tested (Fig. 4 B). These results confirm the previous observa-
tion that T reg cells are a direct cellular target of the CTX plus 
OX86 combination therapy. These results also validate early 
reports showing that OX86 does not deplete OX40-expressing 
cells and remains bound to its cellular target for prolonged   
periods (49, 50). We propose, then, that CTX may increase 
the availability and potency of OX86 by depleting cells im-
portant for antibody clearance, additionally explaining the 
basis for CTX and OX86 synergy.
Combination therapy expands T reg cells in the periphery
Previous results show T reg cells to be a primary target of the 
CTX plus OX86 treatment. Therefore, we investigated the 
biological effects of the combination therapy on T reg cells 
in vivo. We injected groups of mice with CTX or PBS, fol-
lowed by OX86 or rat IgG 1 d later, and analyzed popula-
tions of splenocytes at day 15. Interestingly, we found an 
increase in the percentage of T reg cells when OX86 or 
CTX was administered alone (Fig. 5, A and B). Moreover, 
T reg cell expansion was further amplified with the combi-
nation therapy, as we observed an 2.5-fold increase in the 
percentage of T reg cells in mice treated with CTX plus 
OX86 compared with control treatments (Fig. 5, A and B). 
CTX administration modulates the expression of OX40  
on T reg cells
Only cells expressing OX40 can be directly receptive to the 
effects of an agonist anti-OX40 antibody. Hence, we investi-
gated how CTX affects the expression of OX40 in different 
cell subsets. Mice were injected with CTX and spleens were 
harvested on days 0, 1, 2, 4, 7, 11, 17, and 24 after injection. 
Single-cell suspensions were prepared from spleens and ana-
lyzed by flow cytometry for OX40 expression in different cell 
populations. We found that CTX modulated the expression 
of OX40 primarily in CD4+ T cells, but little or no change 
was observed in CD8+ T cells (Fig. 3 A). OX40 expression 
was down-regulated at the nadir of CTX-induced cytopenia 
(day 4) and was up-regulated as cells were recovering from 
lymphopenia (day 11) compared with baseline expression. On 
closer examination, we observed that OX40 expression was 
modulated primarily in the CD4+ Foxp3+ T reg cell popula-
tion, with minimal changes in OX40 expression in CD4+ 
Foxp3 T cells (Fig. 3 B). These results suggest that T reg cells 
are likely to be a direct target of the combination therapy, 
because CTX administration modulated the expression of OX40 
most dramatically in this subset.
Preferential binding of OX86 to T reg cells  
after CTX administration
To determine the in vivo cellular targets responsible for the ef-
fects  of  the  combination  therapy,  we  injected  biotinylated 
OX86 into tumor-bearing mice treated with CTX. On day 21 
after tumor challenge, single-cell suspensions prepared from 
tumor, TDLN, and spleen were stained ex vivo with strepta-
vidin-PE (strep-PE) and analyzed by flow cytometry for the 
Figure 3.  CTX administration modulates OX40 expression on T reg cells. C57BL/6 mice were injected with CTX. Groups of four mice were sacri-
ficed on days 0, 1, 2, 4, 7, 11, 17, and 24 after CTX injection, and splenocytes were analyzed by flow cytometry for OX40 expression. (A) The percentage 
of OX40+ events gated on CD4+ and CD8+ T cells. A representative histogram depicting day 0 is shown (right). (B) OX40 mean fluorescence intensity 
(MFI) of CD4+Foxp3+ and CD4+Foxp3 T cells. A representative histogram depicting day 0 is shown. Values represent means ± SEM. The experiment was 
repeated three times with similar results.JEM VOL. 206, May 11, 2009 
ARTICLE
1107
T reg cell expansion was confirmed by the proliferation 
marker Ki67, where greater numbers of T reg cells stained 
positive with the combination therapy compared with con-
trols (Fig. 5 A). Only a small increase in Ki67+ CD4+ Foxp3 
cells was observed in the CTX-treated groups, presumably 
as a result of homeostatic proliferation of effector CD4+ 
T cells. Thus, the combination therapy leads to a T reg cell–
specific expansion.
Recent reports have shown that OX40 engagement can 
block the suppressive function of Foxp3 T reg cells (32–34). 
We purified CD4+ CD25+ cells from treated mice and per-
formed ex vivo suppression assays to test if this observation 
holds true for T reg cells expanded in vivo. We found no dif-
ference in the suppressive capabilities of T reg cells purified 
from  mice  treated  with  combination  and  control  therapies 
(Fig. S1). Similar results were obtained when sorted CD4+ 
Foxp3eGFP
+ cells were used in the assay (unpublished data).
Overall, these results indicate that OX40 engagement pro-
motes the expansion of bona fide T reg cells in vivo, an effect 
that is greatly amplified by the combination with CTX. This 
Figure 4.  Preferential binding of OX86 in vivo to T reg cells after CTX administration. C57BL/6 mice (n = 3–4 per group) were inoculated with 
B16-Matrigel. On day 6, mice received CTX and were then injected with biotinylated OX86 or PBS on day 7. Single-cell suspensions were prepared on  
day 21 from tumor, TDLN, and spleen, and were stained with strep-PE in addition to phenotypic markers. The samples were analyzed by flow cytometry.  
(A) Representative histograms of CD4+ and CD8+ T cells (percentages are shown). (B) Representative histograms of CD4+ Foxp3+ and CD4+ Foxp3 T cells. 
The experiment was repeated two times with similar results.
Figure 5.  CTX OX86 combination therapy induces T reg cell expansion. C57BL/6 mice (n = 4 per group) were injected with CTX or PBS on day 1 
and received OX86 or rat IgG on day 2. On day 15, splenocytes were prepared and analyzed by flow cytometry. (A) Representative histogram showing 
the Ki67 profiles of CD4+ Foxp3+ and CD4+ Foxp3 T cells from different treatment groups (percentages are shown). (B) Percentage of Foxp3+ cells in 
the CD4+ gate with different treatments. The experiment was repeated five times with similar results. Horizontal bars represent means. *, P < 0.05.1108 OX40 ENGAGEMENT AND CHEMOTHERAPY SYNERGIZE TO PROVIDE POTENT ANTITUMOR IMMUNITY | Hirschhorn-Cymerman et al.
Figure 6.  CTX OX86 combination therapy decreases the levels of tumor-infiltrating T reg cells concomitantly with CD8+ T cell tumor infil-
tration. (A–D) C57BL/6 mice (n = 3–5 per group) were inoculated with B16-Matrigel. On day 6, mice were injected with CTX or PBS followed by OX86 or 
rat IgG on day 7. Single-cell suspensions were prepared on day 13 or 21 from tumor and TDLN, and were analyzed by flow cytometry. Non–CTX-treated JEM VOL. 206, May 11, 2009 
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observation is quite puzzling given the potent antitumor effects 
of the combination therapy.
Combination therapy decreases T reg cells in the tumor 
concomitantly with an increased infiltration of CD8+ T cells 
that results in a favorable T effector/T reg cell ratio
Although elevated T reg cell levels have been associated with 
a clinically unfavorable prognosis (51), our data show an in-
crease in the proliferation of splenic T reg cells after treat-
ment. Therefore, we investigated the effect of the combination 
therapy on cells present within the tumor microenviron-
ment. Mice bearing B16-Matrigel tumors were treated with 
CTX on day 6 and OX86 or rat IgG on day 7, and tumors 
and TDLNs were analyzed by flow cytometry 1 wk later 
(day 13). As shown in Fig. 6 (A and C), we observed a pro-
found depletion of T reg cells in the tumor and TDLN in 
groups treated with CTX regardless of antibody treatment. 
This resulted in decreased absolute numbers of T reg cells at 
these sites (unpublished data).
To understand the antitumor synergy of CTX plus OX86, 
we evaluated the effect of the combination therapy on cells 
present within the tumor and TDLN 2 wk after treatment 
(day 21). We observed that 50% of CD4+ T cells infiltrating 
the tumor were T reg cells in the CTX plus IgG control group, 
whereas CTX plus OX86–treated mice showed a substantial 
reduction in T reg cell infiltration (13%; Fig. 6, B and C). In 
contrast, the frequency of T reg cells present in the TDLN in-
creased with the combination therapy compared with con-
trols. We did find a modest increase of 30% in the number 
of CD4+ Foxp3 cells infiltrating the tumor; however, the 
combination therapy consistently decreased the absolute num-
ber of T reg cells in the tumor and increased T reg cell levels 
in the TDLN on day 21. (Fig. 6 B and not depicted).
On day 21 we also observed a substantial increase in 
CD8+ T cells within tumors of mice that received CTX 
plus OX86 combination therapy (Fig. 6 D). Thus, the com-
bination therapy decreased the numbers of tumor-infiltrat-
ing T reg cells while simultaneously increasing the levels of 
effector T cells. A decreased intratumoral T reg/T effector 
cell ratio is a hallmark of many successful immunotherapies, 
as demonstrated for a variety of human cancers and mouse 
tumor models (2, 46, 52).
To test whether the lower numbers of infiltrating T reg 
cells in the tumor and the higher numbers in the periphery 
were caused by a direct effect of the combination therapy on 
T reg cells, we adoptively transferred OX40+/+ or OX40/ 
purified CD4+ cells into tumor-bearing OX40/ recipients 
that were treated with CTX. As a control, we included a 
group that received wild-type splenocytes. 4 h after adoptive 
transfer, OX86 was administered to all groups. 5 d later, 
spleens, TDLN, and tumors were analyzed by flow cytome-
try. As shown in Fig. 6 E, lower levels of T reg cells infil-
trated the tumor in mice that received OX40+/+ CD4+ cells 
or wild-type splenocytes compared with the OX40/ group. 
Higher levels of T reg cells were found in the spleen and 
TDLN of mice receiving wild-type CD4+ cells or spleno-
cytes compared with mice that received OX40/ CD4+ 
T cells. These results confirm that the therapy-induced changes 
in the T reg cell population are caused at least in part by the 
direct targeting of T reg cells.
CTX plus OX86 increases T reg cell activation and apoptosis
We next examined the mechanism leading to lower intratu-
moral T reg cell infiltration with CTX plus OX86 treatment. 
Several reports have demonstrated that the tumor microenvi-
ronment is conducive to the peripheral conversion of CD4+ 
Foxp3 to T reg cells (53). In addition, it was recently reported 
that OX40 engagement can block peripheral conversion   
of induced T reg cells (33, 35). To evaluate the possibility   
that OX86 might block peripheral conversion in our model, 
we transferred FACS-sorted CD4+ Foxp3eGFP
+ or CD4+ 
Foxp3eGFP
 cells into tumor-bearing mice that were pretreated 
with CTX. The next day, mice were injected with OX86 or 
rat IgG. 5 d after cell transfer, we found no tumor-induced 
peripheral conversion in mice that received CD4+ Foxp3eGFP
 
cells (Fig. S2). However, in recipients of CD4+ Foxp3eGFP
+ 
cells, we noted increased accumulation of the transferred cells 
in the TDLN and decreased levels in the tumor. This is con-
sistent with our previous observation and suggests that de-
creased T reg cell infiltration after combination therapy does 
not result from blocked peripheral conversion.
Lower T reg cell levels in the tumor could be explained, 
then, by a preferential lack of proliferation and/or survival. 
We found an increase in T reg cell proliferation in mice treated 
with the combination therapy, as shown by Ki67 staining   
(Fig. 7 A). Furthermore, in the TDLN of mice treated with 
the combination therapy, T reg cells down-regulated CD62L, 
indicating a higher activation phenotype (Fig. 7 B). CD62L 
down-regulation is typically accompanied by the migration of 
T cells to effectors sites. T reg cells present at the tumor site 
were all CD62L low regardless of treatment. We observed that 
T reg cells from mice treated with the combination therapy 
showed a greater down-regulation of CD25 in the TDLN, 
whereas in the tumor, T reg cells from both treatment groups 
mice succumbed to disease before day 21. Representative histograms of CD4 versus Foxp3 cells for day 13 (A) and day 21 (B) are shown (percentages 
are shown). (C) Percentage of CD4+ T cells that are Foxp3+. (D, left) Representative histogram of CD8+ versus Foxp3+ cells in the tumor on day 21 (per-
centages are shown). (middle) Percentage of CD8+ T cells. (right) Ratio of CD8+ T cells/T reg cells. Experiments were repeated five times with similar re-
sults. (E) C57BL/6 OX40/ mice (n = 4–5 mice per group) were injected with B16-Matrigel. On day 6, CTX was administered, and on day 7, 2 × 107 
purified CD4+ T cells from OX40/ or wild-type mice were i.v. injected. A control group received 3 × 107 splenocytes. On the same day, mice were in-
jected with OX86. On day 12, tumors, TDLN, and spleens were analyzed by flow cytometry. The experiment was performed two times with similar results. 
Horizontal bars represent means. *, P < 0.05.
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Figure 7.  The combination of CTX and OX86 increases T reg cell activation and apoptosis. C57BL/6 mice (n = 3–5 per group) were inoculated 
with B16-Matrigel. On day 6, all mice received CTX. On day 7, the mice received a dose of OX86 or rat IgG. Single-cell suspensions were prepared on 
day 21 from tumors and TDLNs and were analyzed by flow cytometry. (A) Representative histogram of Ki67 intracellular staining gated on CD4+ 
Foxp3+ T cells (percentages are shown). (B, top) Representative plot of CD62L staining gated on CD4+ Foxp3+ T cells; (bottom) CD62L MFI of T reg cells 
in tumor or TDLN. (C) CD25 MFI of T reg cell in tumors and TDLNs. (D, top) Representative plot of Bcl-2 intracellular staining of CD4+ Foxp3+ and CD4+ 
Foxp3 T cells; (bottom) Bcl-2 MFI of T reg cells in tumors and TDLNs. Experiments were repeated four times with similar results. (E) C57BL/6 CD45.1 JEM VOL. 206, May 11, 2009 
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were CD25 low (Fig. 7 C). Given that IL-2 signaling is re-
quired for T reg cell survival (54), we hypothesized that T reg 
cell–specific apoptosis caused by hyperactivation by the com-
bination therapy accounts for lower intratumoral T reg cell in-
filtration. Bcl-2 down-regulation occurs at the early stages of 
programmed cell death and has been shown to be a marker of 
T reg cell apoptosis in vivo (55). Bcl-2 was significantly down-
regulated on T reg cells in the TDLN of mice treated with the 
combination  therapy  (Fig.  7  D).  Bcl-2  was  unchanged  on 
CD4+ and CD8+ T cell effector populations, indicating T reg 
cell–specific cell death (Fig. 7 D and not depicted). The ex-
pression of Bcl-2 in all T cell populations tested was lower in 
the tumor than in the TDLN. We observed only marginal in-
creases in the frequency of Annexin V+ and active caspase 3+ 
T reg cells after combination therapy. As apoptotic cells should 
be rapidly removed by the scavenger system in vivo, detection 
of low levels might be expected (56). To increase detection 
sensitivity, we transferred congenic, CFSE-labeled, purified 
CD4+ T cells into B16-bearing mice that were pretreated with 
CTX and later injected with OX86 or control IgG. The com-
bination therapy induced a significantly higher percentage of 
active caspase 3+ and viability dye–positive (57) cells (Fig. 7 E). 
These populations were primarily CFSE low, consistent with 
the previous finding of increased T reg cell proliferation after 
combination therapy (not depicted). Collectively, these results 
imply that lower levels of intratumoral T reg cells caused by 
CTX plus OX86 therapy occur as a result of specific hyperac-
tivation and T reg cell–specific cell death.
DISCUSSION
In this paper, we provide evidence that a chemotherapeutic 
agent routinely used in the clinic (CTX) can greatly enhance 
the antitumor potency of a novel form of immunotherapy 
(OX40 engagement) in an aggressive tumor model in which 
neither therapy alone shows a significant antitumor effect. 
The combination of CTX and OX86 resulted in regression 
and long-term protection of established, poorly immuno-
genic tumors. Mechanistically, we found that killing of the 
tumor by CTX provides the antigen necessary to prime   
an antitumor immune response, and in this setting, OX86 
greatly enhances effector T cell function. On closer exami-
nation, we found T reg cells to be an important target of the 
combination  therapy.  Surprisingly,  OX86  administration 
alone expanded T reg cells in the periphery, an effect that 
was exacerbated in combination with CTX. In the tumor 
microenvironment, however, the combination therapy pro-
moted a favorable T effector/T reg cell ratio by increasing 
the number of CD8 T+ cells and decreasing the number of 
T reg cells. We observed elevated levels of T cell activation 
together with elevated apoptotic markers on T reg cells from 
mice treated with the combination therapy, indicating that 
hyperactivation leads to T reg cell–specific apoptosis within 
the tumor microenvironment.
Numerous studies have shown that alkylating drugs such 
as CTX can potentiate an antitumor immune response (58). 
Our data suggest that CTX-induced tumor destruction lead-
ing to antigen cross-presentation is a mechanism that con-
tributes to the synergy of the combination therapy. This is 
because (a) tumor-bearing but not naive mice subjected to 
the combination therapy were able to mount detectable anti-
gen-specific T cell responses to proteins expressed on B16, 
and (b) tumor-specific T cells (pmel-1) proliferated more vig-
orously with the combination therapy at the TDLN but not 
at a distant site. These results suggest that cross-presentation 
of antigen provided by damaged tumor is an effective way to 
generate an antitumor T cell response and does not require 
the laborious identification of antigenic tumor epitopes.
Several observations indicate that T reg cells are a primary 
target of OX86 when CTX plus OX86 combination therapy 
is administered. First, after CTX administration, T reg cells 
modulated  the  expression  of  OX40  (the  sole  receptor  of 
OX86), whereas the effect on other T cell subsets was mini-
mal. Second, we found OX86-biotin to be bound primarily 
to T reg cells in the tumor, TDLN, and spleen after CTX ad-
ministration, whereas only a small proportion was bound to 
CD8+ and CD4+ T cells. Third, we observed increased T reg 
cell expansion in the spleen and TDLN and decreased levels 
of T reg cell infiltration in the tumor, an effect that was lost in 
an OX40/ background.
When we examined the role of OX40 engagement on 
T reg cells, we found that OX86 injection preferentially ex-
panded T reg cells in the periphery. Because OX40 engage-
ment promotes the clonal expansion of T cells (26), it is 
conceivable that OX86 promotes T reg cell expansion be-
cause T reg cells are in a perpetually proliferative state. (59, 60). 
Additionally, T reg cells are the only OX40-expressing pop-
ulation in naive mice (31, 33, 34). Our observations are consis-
tent with early reports showing that chronic OX40 engagement 
in mice overexpressing OX40L promotes higher T reg cell 
levels (31). It has also been reported that OX40 engagement on 
T reg cells can reduce Foxp3 levels in vitro (33). We observed 
no difference in Foxp3 expression levels after OX86 adminis-
tration in any of our treatments. The reason for this discrep-
ancy is yet to be determined, but the degree of TCR stimulation 
or cytokine milieu that occurs in vivo versus in vitro could   
account for this inconsistency. In addition, we found no differ-
ence in the suppressive function of OX86-expanded T reg 
cells in ex vivo assays.
mice (n = 4 per group) were inoculated with B16-Matrigel. On day 6, mice received CTX. On day 7, mice were injected with purified CD4+, CD45.2+ 
CFSE-labeled cells, and OX86 or rat IgG. On day 12, single-cell suspensions were prepared from TDLN and analyzed by flow cytometry. Events were 
gated on CD45.2+ CD4+ cells. (right) Activated caspase 3 versus CFSE is shown; (left) ViD versus CFSE is shown (percentages are shown). One represen-
tative plot (P < 0.05 for the Foxp3+ CFSE low active Caspase 3+ or ViD+ population) of two independent experiments is shown. Horizontal bars repre-
sent means. *, P < 0.05; **, P < 0.005; and ***, P < 0.0005.
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specific cell death. Indeed, we detected apoptosis specifically 
within the T reg cell population, but not in CD4+ and CD8+ 
T effectors in the TDLN when mice were treated with the 
combination of CTX and OX86. At the tumor site in our 
model, however, T reg cells were apoptotic regardless of 
treatment, consistent with the notion that T reg cells at effec-
tor sites down-regulate Bcl-2 and then die (63).
Based on these results, we propose that the clinical mea-
surement of peripheral T reg cells might not be of diagnostic 
value and that intratumoral levels are of greater importance 
when novel immunotherapies are evaluated. Behaviorally, 
T reg cells might expand or contract depending on the local 
milieu provided by differences in co-stimulation or cytokine 
stimuli. Recently, it was reported that OX40 engagement in 
combination with TNF- induces CD4+ T cell apoptosis in 
vitro (66). Given that the tumor microenvironment is abun-
dant in TNF- and OX86 is bound primarily to T reg cells, 
it is conceivable that this is a potential mechanism for T reg 
cell–specific cell death.
Notably, an imbalance in the ratio of T reg/T effector 
cells as a result of T reg cell–specific apoptosis has been reported 
in a variety of autoimmune diseases. Higher apoptosis was 
found in CD4+ CD25+ T reg cells from patients with type 1 
diabetes (67), whereas elevated numbers of CD4+ CD25+ 
cells undergoing apoptosis in the thyroid are found in patients 
with autoimmune thyroid disease (68). In the nonobese diabetic 
mouse strain, T reg cell apoptosis correlates with diabetes onset 
as a result of IL-2 deficiency (55), whereas immune steato-
hepatitis caused by oxidative stress has been associated with a 
down-regulation of Bcl-2 and an increase in T reg cell apoptosis 
(69). Expression of the proapoptotic molecule Bax under the 
CD25 promoter leads to T reg cell apoptosis and increased 
susceptibility to vasculitis in mice (70). To our knowledge, this 
is the first study to report that potent antitumor immunity can 
be achieved by inducing T reg cell–specific apoptosis.
The suppressive function of T reg cells constitutes a ma-
jor barrier to effective cancer immunotherapy. Most cancers 
“hijack” T reg cells to evade the immune response by active 
recruitment (2), local expansion (4, 71, 72), and conversion 
of naive CD4+ T cells (73, 74). Therefore, strategies that 
can remove or abrogate their function are highly desirable. 
Clinically, the elimination of T reg cells has been achieved 
by targeting CD25 using a fusion protein consisting of IL-2 
linked  to  diphtheria  toxin  (enileukin  diftitox)  (51).  This 
strategy has the unfortunate caveat of potentially eliminating 
activated CD25+ effector T cells as well. In this paper, we 
present evidence that induction of T reg cell–specific cell 
death is an attractive alternative to T reg cell elimination 
because, in addition to decreasing T reg cell levels, the CTX 
plus OX86 combination therapy can enhance the activation 
of T cell effectors, as shown in Fig. 2. Furthermore, intratu-
moral administration of OX86 has been shown to deactivate 
the suppressive function of T reg cells locally (34).
Given the multifactorial nature of cancer as a disease, it is 
unlikely that a single therapy will be an efficacious treatment. 
For this reason, combining conventional cytotoxic therapy 
At certain doses or administration regimens, CTX prefer-
entially depletes T reg cells (12, 13, 16, 61). At the higher 
doses such as those reported in this paper, CTX induced pro-
found lymphopenia. As recovery takes place and T cells un-
dergo homeostatic proliferation, T reg cells are proliferating 
more vigorously than other populations analyzed (Fig. 5). 
This may be because homeostatic proliferation is driven by 
self-MHC–peptide complexes (62), and because the T reg 
cell repertoire is skewed toward self (63), there are greater 
MHC–TCR interactions for T reg cells than for effector T cells. 
OX86 can provide co-stimulation to an already cycling pop-
ulation of cells. Therefore, the addition of OX86 will fuel T reg 
cell expansion even further.
Increased levels of T reg cells are typically associated with 
a negative prognosis in preclinical tumor models and cancer 
patients (51). It is therefore counterintuitive that OX86 and 
CTX results in the peripheral expansion of this population 
because the combination therapy provides such strong anti-
tumor effects. To understand this apparent paradox, we mea-
sured T reg cell levels within the tumor microenvironment 
and found a striking decline in intratumoral T reg cell levels in 
mice subjected to the combination therapy. Our data indicate 
that this decline occurs in two phases: first, an antibody-inde-
pendent phase occurs where CTX induces a profound deple-
tion  of  T  reg  cells  in  the  tumor  microenvironment.  It  is 
plausible that actively proliferating T reg cells within the tu-
mor microenvironment are particularly susceptible to the ef-
fects of CTX and T reg cell repopulation is locally delayed. 
Alternatively, CTX may eliminate cells present within the tu-
mor stroma that are responsible for the recruitment, mainte-
nance, and induction of T reg cells within the tumor. Second, 
at a later time point, tumors repopulate with T reg cells in the 
CTX plus IgG control, whereas with CTX plus OX86 there 
is still a deficiency of T reg cells in the tumor. This is concur-
rent with significant tumor infiltration of CD8+ effector T cells 
that causes a favorable shift in the T effector to T reg cell bal-
ance. A positive T effector/T reg cell ratio has been shown to 
be a hallmark of favorable disease prognosis and positively 
correlates with successful therapies (46, 52). Similar observa-
tions were recently reported by Gough et al., where OX86 
administration in mice with immunogenic tumors promoted 
a favorable T effector/T reg cell ratio (64) .
Closer examination of the tumor microenvironment re-
vealed higher proliferation and activation of T reg cells result-
ing  from  combination  therapy.  T  reg  cells  in  the  TDLN 
expressed higher Ki67 and lower CD62L levels in mice treated 
with the combination therapy, indicating higher proliferation 
and activation. Furthermore, T reg cells in the TDLN ex-
pressed lower levels of CD25. Given that IL-2 signaling is es-
sential for T reg cell homeostasis, a loss of IL-2 sensitivity will 
limit T reg cell survival (65). Furthermore, T reg cells from 
mice lacking CD25 or IL-2 exhibit an activated phenotype, 
suggesting that CD25 down-regulation is characteristic of ac-
tivated T reg cells under certain circumstances (65).
Therefore, we hypothesized that hyperactivation of T reg 
cells within the tumor microenvironment induces T reg cell–JEM VOL. 206, May 11, 2009 
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(LSRII; BD). FlowJo software (version 8.6.2; Tree Star, Inc.) was used for 
all flow cytometry analysis. FACS sorting was conducted on a cell sorter 
(FACSDiva; BD).
ELISPOT assay and peptides. Peptides were synthesized by Genemed 
  Synthesis, Inc. and used at >80% purity, as confirmed by HPLC. Peptide from 
dopachrome tautomerase/tyrosinase–related DCT181 (sequence VYDFFVWL) 
is restricted by Kb (76). Tyrosinase-related protein 1, Tyrp1522, is an I-Ab–
  restricted peptide (sequence RYAYDYEELPNPNHS; unpublished data).
Multiscreen-IP plates (Invitrogen) were coated with 100 µl anti–mouse 
IFN-  antibody  (10  mg/ml;  clone  AN18;  Mabtech)  in  PBS,  incubated 
overnight at 4°C, washed with PBS to remove unbound antibody, and 
blocked with RPMI 1640 plus 7.5% FBS for 2 h at 37°C. CD8+ or CD4+ 
T cells were harvested from pooled spleens from sacrificed mice (3–4 mice 
per group), purified using anti-CD8 or anti-CD4 MACS magnetic beads 
(Miltenyi Biotec), and plated at a concentration of 5 × 104 CD8+ T cells or 
2 × 105 CD4+ T cells per well. For antigen presentation, 5 × 104 irradiated 
B16 cells, EL-4 leukemia cells (American Type Culture Collection), or 105 
T cell–depleted irradiated splenocytes that had been pulsed with 10 µg/ml of 
peptide for 1 h were added to a final volume of 100 µl/well. After incubation 
for 20 h for CD8+ T cells and 48 h for CD4+ T cells at 37°C, plates were 
extensively washed with PBS plus 0.05% Tween and incubated for 2 h at 
37°C with 100 µl/well of biotinylated antibody against mouse IFN- 
(2 mg/ml; clone R4-6A2; Mabtech). Spot development was performed as 
previously described (77). Spots were counted with an automated ELISPOT 
reader system with KS 4.3 software (Carl Zeiss, Inc).
Adoptive transfer experiments. In some experiments, animals received 
2 × 106 CFSE-labeled CD8+ pmel-1 cells intravenously via the lateral tail 
vein. CD8+ T cells were purified (98% pure) from pooled spleens and LNs 
from  pmel-1  mice  by  positive  selection  using  CD8a  (Ly-2)  microbeads 
(Miltenyi Biotec) according to the manufacturer’s instructions. Purified cells 
were stained in PBS with 10 µM CFSE at 37°C for 10 min and quenched in 
complete media. The cells were washed twice in PBS before transfer.
In other experiments, OX40/ animals received 2 × 107 purified 
CD4+ T cells from OX40/ or wild-type mice or 3 × 107 splenocytes 
from wild-type mice. CD4+ T cells were purified by MACS using CD4 
(L3T4) microbeads (Miltenyi Biotec). Purity was confirmed by flow cytom-
etry to be 98%.
For the in vivo conversion assay, FACS-sorted CD4+ Foxp3eGFP
+ and 
CD4+ Foxp3eGFP
 cells were transferred into B16-Matrigel tumor-bearing 
mice pretreated with CTX and then treated with either OX86 or IgG.
In vivo apoptosis experiments were performed by injecting CD45.1 
mice with B16-Matrigel. 6 d later, the mice were injected with CTX. On 
day 7, the mice were injected with 107 purified CD4+ cells from CD45.2 
mice labeled with 10 µM CFSE. 4 h later, the mice were injected with 
OX86 or rat IgG. On day 12, single-cell suspensions were prepared from 
DLNs and analyzed by flow cytometry.
T reg cell suppression assays. T reg cell suppression assays were performed 
with a modified method from Thornton et al. (78). In brief, CD4+ CD25+ 
T reg cells were purified by MACS using a regulatory T cell isolation kit 
(Miltenyi Biotec) from spleens of treated animals. 5 × 104 T reg cells were 
co-cultured at a 1:1 ratio with CFSE-labeled (1 µg/ml) Thy1.1 congenic 
CD8+ T cells purified by MACS positive selection (Miltenyi Biotec) in the 
presence of 1 µg/ml of plate-bound anti-CD3 antibody. After 96 h, the CD8+ 
T cell proliferation was analyzed by flow cytometry.
Statistical  calculations.  Statistical  differences  between  experimental 
groups were determined by the two-tailed Student’s t test using Prism soft-
ware (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows that the CTX plus OX86 
combination therapy does not alter the suppressive capability of T reg cells 
in vivo. Fig. S2 shows that the blocking of peripheral T reg cell conversion 
does not cause reduced levels of intratumoral T reg cells after treatment with 
with immunotherapy is an attractive approach. A major ad-
vantage of the reported strategy is that it does not require ex 
vivo manipulation or a priori knowledge of tumor antigens 
to provide potent antitumor immunity. Hence, we expect it 
could be easily applicable in patients suffering from a variety 
of malignancies regardless of MHC restriction.
Overall, we present a novel mechanism by which potent 
tumor immunity is attained with the combination of CTX 
and OX40 engagement and show that this treatment induces 
a favorable T effector/T reg cell ratio as a result of T reg 
cell–specific apoptosis within the tumor environment.
MATERIALS AND METHODS
Mice and tumor cell lines. All mouse procedures were performed in accor-
dance with institutional protocol guidelines at Memorial Sloan-Kettering 
Cancer Center (MSKCC) under an approved protocol. C57BL/6J (8–10-wk-
old females) and C57BL/6J Thy1.1 animals, and C57BL/6J CD45.1 animals 
were obtained from the Jackson Laboratory. pmel-1 TCR transgenic mice 
(Thy1.1) were a gift from N. Restifo (National Institutes of Health, Bethesda, 
MD) (48); Foxp3eGFP mice were provided by A. Rudensky (MSKCC, New 
York, NY) (65). OX40/ mice were provided by N. Killeen (University of 
California, San Francisco, San Francisco, CA) (75). All mice were bred at 
MSKCC. The B16-F10 mouse melanoma line was originally obtained from I. 
Fidler (M.D. Anderson Cancer Center, Houston, TX) and passaged intrader-
mally in mice several times to ensure tumor growth. Immunization with 5 × 
104 B16-F10 cells was determined to be a lethal dose. For experiments where 
isolation of tumor lymphocytes was performed, B16-Matrigel was subcuta-
neously injected (2.5 × 105 B16-F10 cells in 0.2 ml of Matrigel Matrix Growth 
Factor Reduced; BD). Without treatment, mice bearing B16-Matrigel tumors 
survived up to days 14–16 after tumor challenge.
Monoclonal antibodies  and  drug  treatment. OX86 hybridoma was 
obtained from the European Collection of Cell Cultures. FGK45 hybridoma 
was obtained from the American Type Culture Collection. 9D9 hybridoma 
was a gift of J.P. Allison (MSKCC, New York, NY). The antibodies were 
produced, purified, and biotinylated where indicated in the figures by the 
Monoclonal Antibody Core Facility at MSKCC. Anti–Rat IgG was pur-
chased from Sigma-Aldrich and reconstituted in sterile PBS before use. For 
all treatments, 0.5 mg OX86 or rat IgG was administered. 0.25 mg FGK45 
and 0.1 mg 9D9 were administered as a single dose, as indicated in the fig-
ures. Cyclophosphamide monohydrate (Sigma-Aldrich) mixed in sterile PBS 
was administered at 250 mg/kg. Both agents were administered as a single 
dose intraperitoneally.
Antibodies, FACS analysis, and cell sorting. The following antibodies 
were used for flow cytometry analysis: CD8-PE–Texas red, CD4-PerCP, 
Ki67-FITC, CD44–Alexa Fluor 700, CD62L–Alexa Fluor 750, CD25–
PE-Cy7, active caspase 3–biotin, strep-PE–Texas red, and CD3 functional grade 
(BD); and OX40-PE, Foxp3-allophycocyanin, Bcl-2–PE, and CD45.2–Alexa 
Fluor 750 (eBioscience). All antibodies were used according to the manu-
facturer’s instructions with the recommended buffers. The Vybrant CFDA 
SE Cell Tracer kit (CFSE), DAPI, and the LIVE/DEAD Fixable Aqua 
Dead Cell Stain kit (ViD) were obtained from Invitrogen and used accord-
ing to the manufacturer’s instructions.
Samples from TDLNs, spleens, and tumors were mechanically dissoci-
ated to obtain a single-cell suspension. Splenocytes were depleted of eryth-
rocytes with ACK lysing buffer (Invitrogen). Lymphocytes were isolated 
from tumors using Percoll (GE Healthcare) gradient centrifugation. Before 
staining, cells were treated with saturating anti-CD16/CD32 (BD) in stain-
ing buffer (2% bovine serum albumin and 10 mM EDTA in PBS) on ice 
for 15 min. Staining of surface antigens was performed in staining buffer on   
ice for 40 min. All intracellular staining was conducted using the Foxp3   
fixation/permeabilization buffer (eBioscience) according to the manufac-
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